SCM
KPTI icon

Stevens Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Stevens Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-968
Closed -$395K – 1108
2015
Q2 		$395K Buy
+968
New +$418K 0.01% 678

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens Capital Management's KPTI Position: Q3 2015 in Review

Stevens Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2015, closing a stake of 968 shares — an estimated $395K sold.

Stevens Capital Management first reported a position in KPTI in Q2 2015 and held it in 1 quarter. The position peaked at $395K in Q2 2015. 89 funds tracked by Wall St. Rank hold KPTI as of Q3 2015.

  • Stevens Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Stevens Capital Management sold 968 Karyopharm Therapeutics shares in Q3 2015, an estimated $395K.
  • Stevens Capital Management first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 1 quarter.
  • Stevens Capital Management's Karyopharm Therapeutics position peaked at $395K in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2015.

Based on Stevens Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.